Upregulated Expression of SHMT2 Predicts Poor Survival of Lung Adenocarcinoma
Conclusions: Our research indicated that elevated SHMT2 expression is strongly linked to adverse clinical characteristics and poor prognosis in LUAD patients. Consequently, SHMT2 may represent a novel prognosis marker and a promising therapeutic target regarding the treatment of LUAD.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Genetics Research |
| Online Access: | http://dx.doi.org/10.1155/genr/6104753 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|